5-Acetonylcyclohexa-1,3-dien | 50983-19-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-Acetonylcyclohexa-1,3-dien
• 英文别名: 1-Cyclohexa-2,4-dien-1-ylpropan-2-one
• CAS: 50983-19-2
• 化学式: C₉H₁₂O
• 分子量: 136.194
• InChiKey: MYFQSKOZYIFDJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
  申请人：Kirin Pharma Kabushiki Kaisha

  公开号：EP2088141A2

  公开（公告）日：2009-08-12

  An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X = CH or N; Z = O or S; L = O or S; M = CR10R11, wherein R10 and E11 = H, alkyl, or alkoxy, NR12 wherein R12 = H or alkyl; R1, R2, and R3 = H or optionally substituted alkoxy; R4 = H; R5-8 = H, halogen, alkoxy or the like; and R9 = alkyl optionally substituted by -R14, -T-R15, or -NR16R17 wherein T = O, S, or NH; R14 = an optionally substituted carbocyclic or heterocyclic ring; and R15-17 = alkyl or an optionally substituted carbocyclic or heterocyclic ring, or -NR18R19 wherein R18 and R19 = H, optionally substituted alkyl, or an optionally substituted carbocyclic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.

  本发明的目的是提供具有强效抗肿瘤活性的化合物。本发明的化合物由式（I）或其药学上可接受的盐或溶液表示： 其中 X = CH 或 N；Z = O 或 S；L = O 或 S；M = CR10R11，其中 R10 和 E11 = H、烷基或烷氧基，NR12，其中 R12 = H 或烷基；R1、R2 和 R3 = H 或任选取代的烷氧基；R4 = H；R5-8 = H、卤素、烷氧基或类似物；R9 = 任选被 -R14、-T-R15 或 -NR16R17 取代的烷基，其中 T = O、S 或 NH；R14 = 任选取代的碳环或杂环；以及 R15-17 = 烷基或任选取代的碳环或杂环，或 -NR18R19 其中 R18 和 R19 = H、任选取代的烷基或任选取代的碳环或杂环，或任选取代的碳环或杂环。
• CELLULOSE ACETATE FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE WHICH ARE MADE USING SAME
  申请人：Konica Minolta Advanced Layers, Inc.

  公开号：EP2565228A1

  公开（公告）日：2013-03-06

  Provided is a cellulose acetate film which has excellent retardation properties and exhibits low haze even under high-temperature and high-humidity conditions and which, in an alkaline saponification step, causes little dissolution of the film itself or additives in a saponifying liquid. The cellulose acetate film is characterized by comprising: a cellulose acetate which has an acetyl substitution degree of 2.0 to 2.5; and 5 to 15% by mass (relative to the cellulose acetate) of a component which contains a compound represented by general formula (1) wherein m is 0 and a compound represented thereby wherein m is more than 0 at a ratio of 45:55 to 0:100. In general formula (1), G is a mono- or di-saccharide residue; X1 is -O-; R1 is -CO-R2; R2 is an aliphatic or aromatic group; m represents the total number of hydroxyl groups directly bonded to the mono- or di-saccharide residue; and n represents the total number of OR1 groups directly bonded to the mono- or di-saccharide residue, with the proviso that m and n satisfy the relationships: 3 ≤ m+n ≤ 8 and n is not 0.

  本发明提供了一种醋酸纤维素薄膜，它具有优异的缓凝性能，即使在高温高湿条件下也能表现出较低的雾度，而且在碱性皂化步骤中，薄膜本身或添加剂在皂化液中的溶解度很小。醋酸纤维素薄膜的特征在于：醋酸纤维素的乙酰取代度为 2.0 至 2.5；以及 5%至 15%（相对于醋酸纤维素质量）的组分，该组分包含通式（1）所代表的化合物，其中 m 为 0，以及通式（1）所代表的化合物，其中 m 大于 0，两者的比例为 45:55 至 0:100。在通式(1)中，G 是单糖或二糖残基；X1 是-O-；R1 是-CO-R2；R2 是脂肪族或芳香族基团；m 代表直接键合在单糖或二糖残基上的羟基总数；n 代表直接键合在单糖或二糖残基上的 OR1 基团总数，但 m 和 n 满足以下关系：3≤m+n≤8 且 n 不为 0。
• SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES
  申请人：3M Innovative Properties Company

  公开号：EP1765348B1

  公开（公告）日：2016-08-03
• Medication Adherence Monitoring System
  申请人：Melker Richard J.

  公开号：US20100255598A1

  公开（公告）日：2010-10-07

  The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An embodiment of the invention comprises a parent therapeutic agent labeled with a marker, where upon metabolism (e.g., via enzymatic action) of the therapeutic agent, the marker becomes volatile or semi-volatile and is present in the breath. In certain related embodiments, the marker contain a deuterium label, which is also present in the breath upon metabolism of the therapeutic agent. In another embodiment of the invention, the therapeutic agent is associated with a taggant (that may be either labeled or unlabeled with deuterium), which in turn will generate a marker in the breath that is easily measurable.